NCT07476326 2026-03-17
Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
Biocon Limited
Phase 1 Not yet recruiting
Biocon Limited
Vanderbilt-Ingram Cancer Center
M.D. Anderson Cancer Center
Boehringer Ingelheim
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of Iowa
University of Hawaii
Case Comprehensive Cancer Center
M.D. Anderson Cancer Center
University Medical Center Groningen